The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
Hee-Je KimDuring the 61st American Society of Hematology (ASH) meeting in Orlando, US, the AML Global Portal were delighted to speak to Hee‐Je Kim, The Catholic University of Korea, Seoul, KR. We asked: How can we improve outcomes after allogeneic stem cell transplant in patients with acute myeloid leukemia?
Hee‐Je Kim discusses adult patients with AML that undergo allogeneic stem cell transplantation (allo-HScT), he explains there associated toxicities and complications with allo-HSCT, such as GvHD. He also talks about the importance of using MRD status to monitor response to treatment and relapse. Hee-Je Kim also reports data from trials that investigate antileukemic CTLs in high-risk patients with AML. He concludes by discussing different approaches to lessen GvHD
How can we improve outcomes after allo-HSCT in patients with AML?